Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Standard BioTools Inc. (NASDAQ: LAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Forms 10-K, 10-Q and 8-K. These documents offer detailed information about its analytical laboratory instrument manufacturing business, which focuses on SomaScan, mass cytometry and microfluidics technologies used in proteomics and genomics research.
Current reports on Form 8-K are particularly important for tracking material events at Standard BioTools. Recent 8-K filings describe quarterly financial results, including revenue from continuing operations and segment performance, as well as operational restructuring plans involving reductions in force and the consolidation of South San Francisco-based R&D into the company’s Singapore facility. Other 8-Ks detail governance and compensation matters, such as changes to equity incentive plans and retention awards for senior executives.
A key filing for LAB is the Form 8-K describing the Stock Purchase Agreement with Illumina, Inc., under which Illumina will acquire SomaLogic, Inc. and related entities that operate Standard BioTools’ aptamer-based and functional proteomics business. This filing outlines the transaction structure, cash consideration, potential earnouts and royalty arrangements, and the fact that the company’s mass cytometry and microfluidics businesses are being retained.
On Stock Titan, these SEC filings are updated from EDGAR and paired with AI-powered summaries that highlight the main points, such as changes in revenue outlook, restructuring costs, or the terms of significant transactions. Users can quickly identify items related to results of operations, exit or disposal activities, and material definitive agreements, and then drill into the full text of each filing for deeper analysis of LAB’s financial condition, strategic direction and corporate governance.
Standard BioTools Inc. (LAB) Form 4 filing dated 06/24/2025 details new equity awards granted to director and ≥10% shareholder Eli Casdin.
- Restricted Stock Units (RSUs): 94,592 RSUs awarded on 06/20/2025; they vest in full on the earlier of 06/20/2026 or one day prior to the next annual meeting, conditional on continued service. Each RSU converts into one common share.
- Stock Options: Option covering 125,660 shares with a $1.05 exercise price, granted 06/20/2025. The option vests in 12 equal monthly installments beginning 07/20/2025 and expires 06/20/2035.
- Post-transaction ownership: 2,901,062 shares held directly. Through affiliated investment funds, Casdin controls an additional 76,075,636 shares (13,939,637 via Casdin Private Growth Equity Fund II, 2,744,219 via Casdin Private Growth Equity Fund, and 59,391,780 via Casdin Partners Master Fund).
- Role: Casdin is both a director and ≥10% beneficial owner, indicating significant ongoing influence.
No purchase or sale of shares occurred; the awards were granted at no cost, reflecting routine director compensation and aligning incentives with shareholders. The filing does not disclose any earnings data, cash consideration, or changes to company guidance.
Standard BioTools (NASDAQ:LAB) filed a Form 4 disclosing equity awards to director Kathy L. Hibbs executed on 20 Jun 2025.
The filing reports the grant of 94,592 restricted stock units (RSUs) that vest in full on 20 Jun 2026 or one day before the next annual shareholders’ meeting, contingent on continued service. Following the award, Hibbs’ direct ownership increased to 137,720 common shares.
In addition, Hibbs received a stock option for 125,660 shares exercisable at $1.05 per share. The option vests in twelve equal monthly instalments starting 20 Jul 2025 and expires 20 Jun 2035.
No shares were sold; all reported transactions were acquisitions recorded under direct ownership. The activity appears to reflect routine director compensation rather than open-market buying.
Form 4 filing for Standard BioTools Inc. (LAB) dated 24 June 2025 discloses equity compensation granted to board member Frank Witney on 20 June 2025.
Restricted Stock Units (RSUs): Witney received 94,592 RSUs at no cost. The award vests in full on the earlier of 20 June 2026 or one day prior to the company’s next annual shareholder meeting, contingent on continued service. Each RSU converts into one share of common stock upon vesting. After the grant, the director’s direct holdings rise to 210,862 shares; an additional 4,225 shares are held indirectly through a family trust.
Stock Option: He also received a non-qualified option for 125,660 shares with a strike price of $1.05. The option vests in twelve equal monthly installments starting 20 July 2025 and expires 20 June 2035. The filing reports no disposals and no cash paid for the RSUs; any cash impact would occur only if the option is exercised.
The transaction reflects a routine, service-based compensation grant rather than an open-market purchase, aligning director incentives with shareholder value but producing no immediate effect on cash flow or operations. If fully vested and exercised, the awards could increase the company’s outstanding share count by up to 220,252 shares, but the filing provides no data to assess relative dilution.
Standard BioTools Inc. (Nasdaq: LAB) filed an 8-K reporting the outcomes of its 2025 Annual Meeting held on 18 June 2025. Shareholder turnout was high, with 326,864,517 votes cast, representing approximately 86.06% of the 379,822,268 shares outstanding on the 25 April 2025 record date.
The meeting covered four key proposals, all of which passed with comfortable majorities:
- Election of two Class III directors: Kathy Hibbs (96.2% support) and Frank Witney, Ph.D. (97.9% support) were elected to serve until the 2028 annual meeting.
- Say-on-Pay: Executive compensation for FY 2024 received 97.0% shareholder approval (241.1 million FOR vs. 4.0 million AGAINST).
- Auditor ratification: PricewaterhouseCoopers LLP was re-appointed for FY 2025 with 98.8% support (322.9 million FOR).
- Equity Incentive Plan amendment: Shareholders approved increasing the Amended and Restated 2011 Equity Incentive Plan share reserve by 17.4 million shares (223.4 million FOR, 19.6 million AGAINST).
The additional share reserve expands the pool available for future equity grants to employees and directors. Full plan details are provided in Exhibit 10.1, with prior discussion in the company’s 30 April 2025 proxy statement.
No other material transactions, financial results or leadership changes were disclosed in this filing.